의약품부작용보고원시자료(KIDS-KD)를 활용한 baricitinib 및 tocilizumab의 이상사례 분석 및 실마리정보 검색

• 영문명: Adverse Events Analysis and Signal Detection of Baricitinib and Tocilizumab, using KIDS-KD: Focusing on the Adverse Events that may Affect COVID-19
• 발행기관: 대한약학회
• 저자명: 허지영(Ji-Young Hur) 신주영(Ju-Young Shin)
• 간행물 정보: 『약학회지』제66권 제2호(2022년), 49~57쪽, 전체 9쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2022.04.30

영문 초록

Research shows that some severe COVID-19 patients exhibit an excessive inflammatory response with persistent fever; therefore, the drugs that inhibit one or more components of the pro-inflammatory cascade are administered to prevent the worsening of the condition of such patients. According to current updated COVID-19 guidelines, baricitinib and tocilizumab could be administered in COVID-19 patients in certain circumstances. To confirm the safety of these drugs, we analyzed the frequency of the adverse events and detected signals using KIDS-KD. We defined the signals by proportional reporting ratios (PRR), reporting odds ratios (ROR), and information components (IC). “Respiratory system disease” was frequently reported, with both baricitinib (17 cases, 15.0%) and tocilizumab (40 cases, 10.6%). It was also detected as a signal with baricitinib but not with tocilizumab. As the symptoms of COVID-19 are mainly related to the respiratory system, close monitoring is necessary for these patients. In relation to the risk of infection with tocilizumab, leucopenia (18 cases, 4.7%) and granulocytopenia (7 cases, 1.8%) were reported, and leucopenia was detected as a signal. With baricitinib, pyelonephritis was detected as a signal; however, no prior research that supports this finding exists. We expect this study to provide basic data on the safety of administering baricitinib and tocilizumab for COVID-19 patients in certain circumstances.

목차

서론(Introduction)

방법(Methods)

결과(Results)

고찰(Discussion)

결론(Conclusion)

Conflict of Interest

References

키워드

Baricitinib Tocilizumab Adverse events Signal detection KIDS-KD